Cabaletta Bio, Inc. cash flow to debt ratio of -483.73% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Cabaletta Bio, Inc.'s free cash flow has decreased 46.31% from $-90.43M last year to $-132.31M, signaling decreasing performance

Cabaletta Bio, Inc.'s debt to equity ratio is 0.26, which means that the company's assets are healthy financed, signaling financial stability.

Cabaletta Bio, Inc.'s debt has increased relative to shareholder equity from 0.10 last year to 0.26 today, signaling weakened financials

Cabaletta Bio, Inc. has a net cash position, so leverage is healthy.

Cabaletta Bio, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Cabaletta Bio, Inc. has insufficient data to evaluate this check.

Cabaletta Bio, Inc.'s short-term assets of $138.87M exceed its short-term liabilities of $50.15M

Cabaletta Bio, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Cabaletta Bio, Inc.'s return on equity of -131.58%, is lower than 15.00%, indicating bad performance

Cabaletta Bio, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Cabaletta Bio, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Cabaletta Bio, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Cabaletta Bio, Inc. has negative free cash flow, indicating cash burn

Cabaletta Bio, Inc.'s yearly earnings has decreased 44.87% since last year from $-115.86M to $-167.86M, signaling decreasing performance

Cabaletta Bio, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -138.26% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Cabaletta Bio, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Cabaletta Bio, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Cabaletta Bio, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Cabaletta Bio, Inc. has insufficient data to evaluate this check.

Cabaletta Bio, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Cabaletta Bio, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Cabaletta Bio, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Cabaletta Bio, Inc. has insufficient data to evaluate this check.

Cabaletta Bio, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Cabaletta Bio, Inc. has a price-to-book ratio of 3.04x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Cabaletta Bio, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue